

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number 14-15009-01

Docket or Reference number 030-08407

Amendment No. 19

Mercy Hospital
701 Tenth Street, S.E.
Cedar Rapids, IA 52403

In accordance with letter dated June 24, 1985, License Number 14-15009-01 is amended as follows:

Condition 12. is amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

John H. Lohnes, M.D.

Groups I, II, III, IV, V and VI
Xenon-133
In vitro studies

D. R. Charipar, M.D.

Groups I, II and III
Xenon-133
In vitro studies

R. F. Fiester, M.D.

Group I

F. M. Skopec, M.D.

Group I

A. C. Hass, M.D.

All

Dale L. Roberson, M.D.

Groups II, III, IV and VI
Xenon-133

Werner J. Friesen, M.D.

Groups II, III, IV and VI
Xenon-133

John Hess, M.D.

Groups II, III, IV and VI
Xenon-133

Ronald R. Gambach, M.D.

Groups II, III, IV and VI
Xenon-133

Richard L. Kundel, M.D.

Groups I, II and III
Xenon-133
In vitro studies
Iodine-131 for treatment of
hyperthyroidism, cardiac
dysfunction and thyroid carcinoma

8507230133 850708
REQ3 LIC30
14-15009-01 PDR

COPY 2

ML30

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number 14-15009-01

Docket or Reference number 030-08407

Amendment No. 19

Michael Hirleman, M.D.

Groups I, II, III and V
Xenon-133
In vitro studies
Iodine-131 for treatment of
hyperthyroidism and cardiac
dysfunction

William B. Cutcliff, M.D.


Groups I, II and III
Xenon-133
In vitro studies
Iodine-131 for treatment of
hyperthyroidism and cardiac
dysfunction

William R. Neff, M.D.

Groups I, II and III
Xenon-133
Iodine-131 for treatment of
hyperthyroidism, cardiac
dysfunction and thyroid carcinoma.

Hamed Tewfik, M.D.

Groups I, II, III, IV, V and VI
Xenon-133



For the U.S. Nuclear Regulatory Commission

Original Signed

By Evelyn R. Matson

Materials Licensing Section, Region III

Date July 8, 1985

COPY